Rainbow Coral narrows list of regenerative medicine targets

13 November 2013

USA-based Rainbow Coral Corp (OTCBB: RBCC) says it has opened talks with its top target in the regenerative medicine industry this week regarding a possible partnership or acquisition.

RBCC’s potential target specializes in relieving chronic back pain from degenerative disc disease using an innovative, patentable remedy derived from a patient’s own cells. The new procedure could have the potential to ease the suffering of billions of people while helping give RBCC a strong foothold in the explosive regenerative medicine market.

“We’ve targeted the most promising technology and development team we could find in this space because we believe in their product,” said RBCC chief executive Patrick Brown, adding: “We plan to get an agreement signed with them as soon as possible in order to begin making RBCC a part of the solution for chronic pain sufferers worldwide.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK